Zai Lab to present Phase 1/1b healthy-volunteer data for atopic disease antibody ZL-1503 at ACAAI 2026
Bitget2026/10/14 11:00- Zai Lab flagged first clinical data for ZL-1503, a bispecific antibody for atopic diseases, from its Phase 1/1b healthy-volunteer trial.
- Results have not been presented yet; the initial readout is scheduled for the ACAAI 2026 meeting on Nov. 13.
- The update will cover how the drug behaved in the body, early biomarker effects, and initial safety and immunogenicity observations.
- Zai Lab positioned the program as a potentially longer-acting approach aimed at reducing itch and inflammation in IL-13- and IL-31-driven conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
